ReviewClinical microbiology reviews2010
Rifampin combination therapy for nonmycobacterial infections.
Review in Clinical microbiology reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis.PloS one · 2020Pooled it
- The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011Guideline
- A prospective pharmacokinetic interaction study between rifampicin and fusidic acid for the treatment of staphylococcal infections.The Journal of antimicrobial chemotherapy · 2026Trial
- Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial.Journal of orthopaedic surgery and research · 2020Trial
- Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2018Trial
- Detection of livestock-associated MRSA ST398/t011 and hospital-associated MRSA ST239/t037 in a referral hospital in northeastern Iran: A six-month cross-sectional surveillance study (July-December 2025).New microbes and new infections · 2026Article
- Detection ofVeterinary sciences · 2026Article
- Subinhibitory Concentrations of Rifampicin Synergize with Linezolid to Delay Resistance Evolution in Clinical Methicillin-Resistant Staphylococcus Aureus.Microorganisms · 2026Article
- Article
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- Article
- Detection of a Mixed-Strain Infection with Drug- and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Strategic re-engineering of antibiotics.Nature reviews bioengineering · 2025Article
- Optimizing Antimicrobial Use in Japan: Strategies for Dosage, Combination Therapy, De-Escalation, Oral Switching, Duration, and Guideline Adherence.Clinical pharmacology : advances and applications · 2025Review
- Reassessment of the genetic basis of natural rifampin resistance in the genus Rickettsia.MicrobiologyOpen · 2024Article
- Modern Microbiological Methods to Detect Biofilm Formation in Orthopedy and Suggestions for Antibiotic Therapy, with Particular Emphasis on Prosthetic Joint Infection (PJI).Microorganisms · 2024Review
- Review
- The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Evaluating generalizability of artificial intelligence models for molecular datasets.bioRxiv : the preprint server for biology · 2024Article
- Antibiotics with antibiofilm activity - rifampicin and beyond.Frontiers in microbiology · 2024Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.